Please ensure Javascript is enabled for purposes of website accessibility Time to Allocate to Fixed Income
hk
en
institutional
institutional
false
true
Gathering data
Disclaimer Not Available

Time to Allocate to Fixed Income

Time to Allocate to Fixed Income

Income-based returns are back, and investors no longer need to risk equity-type drawdowns or sacrifice liquidity to achieve their investment objectives. In our view, it is an opportune time to increase fixed income allocations. 

As US equities continue to dominate the MSCI World Index with increasing concentration risks, fixed income markets offer potential for improved risk-adjusted returns and reduced volatility due to four key factors: 

  • Yield is back, and we believe it’s here to stay: Yields in many areas of the fixed income market are now close to – or even above – the long-term returns of the MSCI World Index.
  • Yields are just the starting point for returns: Active management has the potential to exploit market dislocations in higher-return segments without compromising liquidity.
  • More consistent returns, lower drawdown risk and diversification benefits: Income-based returns are more predictable, and bond markets have historically had far lower volatility than equity markets.
  • Corporate credit fundamentals remain robust: The role of corporate treasurers is becoming more strategic. The resilience of corporate balance sheets and steepening yield curves further reinforce the strength of the asset class at this stage of the cycle.

The value of investments can fall. Investors may not get back the amount invested. Income from investments may vary and is not guaranteed.


Important Information

For sole and exclusive use by Institutional Investors, Accredited Investors and Professional Investors only. Not for further distribution. This is a financial promotion and is not investment advice. Any views and opinions are those of the investment manager, unless otherwise noted. The value of investment can fall. Investors may not get back the amount invested. BNY, BNY Mellon and Bank of New York Mellon are the corporate brands of The Bank of New York Mellon Corporation and may also be used to reference the corporation as a whole and/or its various subsidiaries generally.  BNY Investments encompass BNY Mellon’s affiliated investment management firms and global distribution companies.  Any BNY entities mentioned are ultimately owned by The Bank of New York Mellon Corporation. In Hong Kong, the issuer of this document is BNY Mellon Investment Management Hong Kong Limited, which is registered with the Securities and Futures Commission (Central Entity Number: AQI762). In Singapore, this document is issued by BNY Mellon Investment Management Singapore Pte. Limited, Co. Reg. 201230427E. Regulated by the Monetary Authority of Singapore (MAS). This advertisement has not been reviewed by the Monetary Authority of Singapore. 


MC669-08-12-2025 (6M)

RELATED CONTENT
Global Short-Dated High Yield: Why spreads don’t tell the whole story
Article | Fixed Income

Cathy Braganza, senior portfolio manager at BNY Investments, explains why tightening spreads with high yields create a potentially attractive risk-return balance for credit investors.

Musical Chairs in Fixed Income
Article | Fixed Income

Leaders rotate in and out. No single fixed income sector consistently dominates performance over time, and strong performance in one sector rarely carries over from one year to the next. For example, U.S. Treasury bills led in 2018 and 2022 but are one of the weakest performers year-to-date.

Healthy correction?
Article | Macroeconomic

After climbing 17% year to date through late October, the S&P 500 declined 5% through November 20. We believe the market was due for a healthy correction. While further downside is possible, it would not concern us.

Novo Nordisk: rethinking the playbook
Article | Macroeconomic

Direct-to-client (DTC) health platforms and personalized compounded treatments may become standard practice in the rapidly evolving obesity treatment market. BNY Investments analyst Dr Oriana Beaumont believes that Novo Nordisk’s recent changes will help position them to effectively compete in this exciting and vast market.

Gathering data
Disclaimer Not Available

CONTACT US  |  +852 3926 0600  |  cs.im.apac@bny.com